Core Insights - American Shared Hospital Services reported a year of transition and operational expansion in 2025, integrating new radiation therapy centers and enhancing treatment capabilities [4] - The company announced a seven-year extension of its Proton Therapy lease agreement with Orlando Health, emphasizing long-term partnerships in cancer care [4] - The focus for 2026 includes optimizing operations, expanding patient access, and pursuing strategic growth opportunities [4] Financial Highlights - For the full year 2025, total revenue decreased by 0.9% to $28.1 million compared to $28.3 million in 2024 [16] - The net loss for 2025 was $1.6 million or $0.23 per share, a decline from a net income of $2.2 million or $0.33 per share in 2024 [19] - Adjusted EBITDA for 2025 was $5.5 million, down from $8.9 million in 2024 [20] Segment Performance Direct Patient Care Services - Revenue from direct patient care services increased by 23.7% year-over-year to $15.5 million, driven by new centers in Rhode Island and Puebla, Mexico [16] - LINAC revenue reached $11.5 million, up 35.4% year-over-year, while Gamma Knife revenue was $9.2 million, down 5.5% [5][16] - The direct patient care services segment represented 63% of total sales in Q4 2025, compared to 52% in the prior year [13] Medical Equipment Leasing - Leasing revenue decreased by 33.9% to $2.9 million in Q4 2025, primarily due to the expiration of three Gamma Knife agreements and lower Proton Beam Radiation Therapy volumes [14][17] - Same-center Gamma Knife procedures increased by 11.3%, supported by equipment upgrades [10] Operational Developments - The company completed the upgrade of its Gamma Knife unit in Lima, Peru, enhancing treatment capabilities [6] - The Rhode Island centers and the Puebla center contributed to increased patient volumes and revenue growth [7] Balance Sheet Highlights - As of December 31, 2025, cash and cash equivalents were $3.7 million, down from $11.3 million a year earlier, reflecting capital investments [21] - Total current portion of long-term debt was approximately $17.3 million, with ongoing discussions with lenders regarding financial covenants [22] - Shareholders' equity was $24.0 million or $3.66 per share, compared to $25.2 million or $3.92 per share at the end of 2024 [23]

Core Viewpoint - American Shared Hospital Services (AMS) is set to hold a conference call on March 31, 2026, to discuss its fourth quarter and full year 2025 financial results, with a press release to be issued before market opening on the same day [1][2]. Group 1: Conference Call Details - The conference call will take place at 12:00 PM ET on March 31, 2026 [1]. - Domestic callers can join by dialing 1-844-413-3972, while international callers can dial 1-412-317-5776 [3]. - A simultaneous webcast will be available on the company's website, and a replay of the call will be accessible until April 7, 2026 [3]. Group 2: Company Overview - AMS is a leading provider of turnkey solutions for cancer treatment centers, health systems, and cancer networks across North and South America [4]. - The company collaborates with partners to enhance cancer service lines and deliver integrated cancer care locally [4]. - AMS shares capital investment costs and profitability with health system partners based on ownership interests [4].

Core Viewpoint - American Shared Hospital Services reported a 17% year-over-year revenue growth for Q1 2025, driven by strategic expansions and operational strengths despite some declines in treatment volumes [4][6]. Financial Performance - Revenue for Q1 2025 was $6.1 million, up from $5.2 million in Q1 2024, primarily due to expanded radiation therapy services [4][6]. - Direct patient services revenue surged by 224% to $3.1 million, attributed to the acquisition of Rhode Island centers and the new facility in Puebla, Mexico [4][6]. - Revenue from the medical equipment leasing segment decreased to $3.0 million from $4.3 million, influenced by lower Gamma Knife volumes and contract expirations [5][6]. Operational Highlights - The company experienced a gross margin of $942,000 in Q1 2025, down from $2.1 million in Q1 2024, mainly due to lower treatment volumes [7]. - A net loss of $625,000 was reported for Q1 2025, compared to a net income of $119,000 in the same period last year [7][16]. - Adjusted EBITDA for Q1 2025 was $0.9 million, a decrease from $1.7 million in Q1 2024 [8][18]. Strategic Initiatives - The company is optimistic about future growth, with plans for further acquisitions and operational efficiencies to enhance profitability [3][6]. - New facilities in Rhode Island and Mexico are expected to contribute to long-term growth, with a focus on expanding direct patient care services [3][4]. Balance Sheet Overview - As of March 31, 2025, cash and cash equivalents totaled $11.5 million, slightly up from $11.3 million at the end of 2024 [9][17]. - Shareholders' equity was reported at $24.6 million, down from $25.2 million at the end of the previous year [9][17].